Increasing demand for one-time therapies for metabolic disorders and rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market.
Market Analysis and Insights: Global Metabolic Disorder Therapeutics Market
The research report studies the Metabolic Disorder Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Metabolic Disorder Therapeutics market size is projected to reach US$ 61900 million by 2026, from US$ 48120 million in 2020, at a CAGR of 4.3% during 2021-2026.
Global Metabolic Disorder Therapeutics Scope and Segment
The global Metabolic Disorder Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Metabolic Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
by Application, this report covers the following segments
Oral
Parenteral
Others
Global Metabolic Disorder Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Metabolic Disorder Therapeutics key players in this market include:
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Market Analysis and Insights: Global Metabolic Disorder Therapeutics Market
The research report studies the Metabolic Disorder Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Metabolic Disorder Therapeutics market size is projected to reach US$ 61900 million by 2026, from US$ 48120 million in 2020, at a CAGR of 4.3% during 2021-2026.
Global Metabolic Disorder Therapeutics Scope and Segment
The global Metabolic Disorder Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Metabolic Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
by Application, this report covers the following segments
Oral
Parenteral
Others
Global Metabolic Disorder Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Metabolic Disorder Therapeutics key players in this market include:
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
1 Market Overview of Metabolic Disorder Therapeutics
1.1 Metabolic Disorder Therapeutics Market Overview
1.1.1 Metabolic Disorder Therapeutics Product Scope
1.1.2 Market Status and Outlook
1.2 Global Metabolic Disorder Therapeutics Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Metabolic Disorder Therapeutics Market Size by Region (2015-2026)
1.4 Global Metabolic Disorder Therapeutics Historic Market Size by Region (2015-2020)
1.5 Global Metabolic Disorder Therapeutics Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2026)
1.6.1 North America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2026)
1.6.2 Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2026)
1.6.4 Latin America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2026)
2 Metabolic Disorder Therapeutics Market Overview by Type
2.1 Global Metabolic Disorder Therapeutics Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2015-2020)
2.3 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2021-2026)
2.4 Lysosomal Storage Diseases
2.5 Diabetes
2.6 Obesity
2.7 Inherited Metabolic Disorders
2.8 Hypercholesterolemia
3 Metabolic Disorder Therapeutics Market Overview by Application
3.1 Global Metabolic Disorder Therapeutics Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2015-2020)
3.3 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2021-2026)
3.4 Oral
3.5 Parenteral
3.6 Others
4 Global Metabolic Disorder Therapeutics Competition Analysis by Players
4.1 Global Metabolic Disorder Therapeutics Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2019)
4.3 Date of Key Manufacturers Enter into Metabolic Disorder Therapeutics Market
4.4 Global Top Players Metabolic Disorder Therapeutics Headquarters and Area Served
4.5 Key Players Metabolic Disorder Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Metabolic Disorder Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Novo Nordisk A/S
5.1.1 Novo Nordisk A/S Profile
5.1.2 Novo Nordisk A/S Main Business
5.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Products, Services and Solutions
5.1.4 Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.1.5 Novo Nordisk A/S Recent Developments
5.2 Sanofi S.A.
5.2.1 Sanofi S.A. Profile
5.2.2 Sanofi S.A. Main Business
5.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Products, Services and Solutions
5.2.4 Sanofi S.A. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.2.5 Sanofi S.A. Recent Developments
5.3 Boehringer Ingelheim GmbH
5.5.1 Boehringer Ingelheim GmbH Profile
5.3.2 Boehringer Ingelheim GmbH Main Business
5.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Products, Services and Solutions
5.3.4 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.3.5 Eli Lilly and Company Recent Developments
5.4 Eli Lilly and Company
5.4.1 Eli Lilly and Company Profile
5.4.2 Eli Lilly and Company Main Business
5.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Products, Services and Solutions
5.4.4 Eli Lilly and Company Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.4.5 Eli Lilly and Company Recent Developments
5.5 Merck KgaA
5.5.1 Merck KgaA Profile
5.5.2 Merck KgaA Main Business
5.5.3 Merck KgaA Metabolic Disorder Therapeutics Products, Services and Solutions
5.5.4 Merck KgaA Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.5.5 Merck KgaA Recent Developments
5.6 Amgen, Inc.
5.6.1 Amgen, Inc. Profile
5.6.2 Amgen, Inc. Main Business
5.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Products, Services and Solutions
5.6.4 Amgen, Inc. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.6.5 Amgen, Inc. Recent Developments
5.7 AstraZeneca PLC
5.7.1 AstraZeneca PLC Profile
5.7.2 AstraZeneca PLC Main Business
5.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Products, Services and Solutions
5.7.4 AstraZeneca PLC Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.7.5 AstraZeneca PLC Recent Developments
5.8 Actelion Pharmaceuticals Ltd.
5.8.1 Actelion Pharmaceuticals Ltd. Profile
5.8.2 Actelion Pharmaceuticals Ltd. Main Business
5.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Products, Services and Solutions
5.8.4 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.8.5 Actelion Pharmaceuticals Ltd. Recent Developments
5.9 Shire PLC
5.9.1 Shire PLC Profile
5.9.2 Shire PLC Main Business
5.9.3 Shire PLC Metabolic Disorder Therapeutics Products, Services and Solutions
5.9.4 Shire PLC Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.9.5 Shire PLC Recent Developments
5.10 AbbVie, Inc.
5.10.1 AbbVie, Inc. Profile
5.10.2 AbbVie, Inc. Main Business
5.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Products, Services and Solutions
5.10.4 AbbVie, Inc. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.10.5 AbbVie, Inc. Recent Developments
5.11 Biocon Ltd.
5.11.1 Biocon Ltd. Profile
5.11.2 Biocon Ltd. Main Business
5.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Products, Services and Solutions
5.11.4 Biocon Ltd. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.11.5 Biocon Ltd. Recent Developments
5.12 BioMarin Pharmaceutical, Inc.
5.12.1 BioMarin Pharmaceutical, Inc. Profile
5.12.2 BioMarin Pharmaceutical, Inc. Main Business
5.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Products, Services and Solutions
5.12.4 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.12.5 BioMarin Pharmaceutical, Inc. Recent Developments
5.13 Bristol-Myers Squibb Company
5.13.1 Bristol-Myers Squibb Company Profile
5.13.2 Bristol-Myers Squibb Company Main Business
5.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Products, Services and Solutions
5.13.4 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.13.5 Bristol-Myers Squibb Company Recent Developments
5.14 Cipla, Inc.
5.14.1 Cipla, Inc. Profile
5.14.2 Cipla, Inc. Main Business
5.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Products, Services and Solutions
5.14.4 Cipla, Inc. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.14.5 Cipla, Inc. Recent Developments
5.15 CymaBay Therapeutics, Inc.
5.15.1 CymaBay Therapeutics, Inc. Profile
5.15.2 CymaBay Therapeutics, Inc. Main Business
5.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Products, Services and Solutions
5.15.4 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Revenue (US$ Million) & (2015-2020)
5.15.5 CymaBay Therapeutics, Inc. Recent Developments
6 North America
6.1 North America Metabolic Disorder Therapeutics Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Metabolic Disorder Therapeutics Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Metabolic Disorder Therapeutics Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Metabolic Disorder Therapeutics Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
